Xcelerate, Inc. Announces Funding
Xcelerate (OTCQB:XCRT) has secured non-dilutive business funding to support the growth plans of its subsidiary, ESN Group. The funding package includes a working capital line for launching new products in the Ceramedx brand and a Line of Credit to support ongoing marketing programs. The financing is aimed at managing cash flow and supporting ESN Group's expansion in the health and wellness market, which is part of Xcelerate's three-pillar business foundation.
Xcelerate (OTCQB:XCRT) ha ottenuto finanziamenti non diluitivi per sostenere i piani di crescita della sua sussidiaria, ESN Group. Il pacchetto di finanziamento include una linea di capitale circolante per il lancio di nuovi prodotti con il marchio Ceramedx e una linea di credito per sostenere i programmi di marketing in corso. Il finanziamento è destinato a gestire il flusso di cassa e supportare l'espansione di ESN Group nel mercato della salute e del benessere, che fa parte della fondazione aziendale a tre pilastri di Xcelerate.
Xcelerate (OTCQB:XCRT) ha asegurado financiamiento no dilutivo para apoyar los planes de crecimiento de su filial, ESN Group. El paquete de financiamiento incluye una línea de capital de trabajo para el lanzamiento de nuevos productos bajo la marca Ceramedx y una línea de crédito para respaldar los programas de marketing en curso. La financiación está destinada a gestionar el flujo de caja y apoyar la expansión de ESN Group en el mercado de la salud y el bienestar, que es parte de la base comercial de tres pilares de Xcelerate.
Xcelerate (OTCQB:XCRT)는 자회사인 ESN Group의 성장 계획을 지원하기 위해 비희석 비즈니스 자금을 확보했습니다. 이 자금 패키지에는 Ceramedx 브랜드의 신제품 출시를 위한 운영 자본 대출과 ongoing 마케팅 프로그램을 지원하기 위한 신용 대출이 포함됩니다. 이 자금 조달은 현금 흐름 관리를 목표로 하며, ESN Group의 건강 및 웰빙 시장 확장을 지원합니다. 이는 Xcelerate의 3가지 기둥 비즈니스 기반의 일부입니다.
Xcelerate (OTCQB:XCRT) a sécurisé un financement non dilutif pour soutenir les plans de croissance de sa filiale, ESN Group. Le package de financement comprend une ligne de fonds de roulement pour le lancement de nouveaux produits sous la marque Ceramedx et une ligne de crédit pour soutenir les programmes marketing en cours. Le financement vise à gérer la trésorerie et à soutenir l'expansion d'ESN Group sur le marché de la santé et du bien-être, qui fait partie de la fondation commerciale à trois piliers de Xcelerate.
Xcelerate (OTCQB:XCRT) hat nicht verwässernde Unternehmensfinanzierung gesichert, um die Wachstumspläne ihrer Tochtergesellschaft, ESN Group, zu unterstützen. Das Finanzierungspaket umfasst eine Betriebskapitallinie zur Einführung neuer Produkte der Marke Ceramedx sowie eine Kreditlinie zur Unterstützung laufender Marketingprogramme. Die Finanzierung zielt darauf ab, den Cashflow zu steuern und das Wachstum von ESN Group im Bereich Gesundheit und Wellness zu fördern, was Teil der dreisäuligen Unternehmensstruktur von Xcelerate ist.
- Secured non-dilutive funding, preventing shareholder dilution
- Obtained working capital line for new product launches
- Secured Line of Credit for marketing programs
- None.
MAULDIN, SC / ACCESSWIRE / October 31, 2024 / Xcelerate, Inc. (OTCQB:XCRT) (the "Company"), today announced that it has reached an agreement for business funding to support the growth plan for the ESN Group, a subsidiary of the Company.
"Xcelerate's leadership continues to cultivate industry interest in its business model and our 3 pillar business foundation. Our near term focus is on ESN Group and its product offering in the health and wellness market. We have recently negotiated business funding to support these initial growth plans for ESN Group. This funding package is non-dilutive to Xcelerate, Inc." commented Mike O'Shea, CEO of Xcelerate, Inc.
Jay Kline, President of ESN Group commented "These funding arrangements include a working capital line for the launch of new products in the Ceramedx brand and a Line of Credit to support ongoing marketing programs which are intended to smooth the timing of revenues and expenses and other cash flow issues".
Investors and shareholders are encouraged to stay updated on the latest developments by visiting the Company's website at https://xcelerate.global.
ABOUT XCELERATE INC.
In May 2020, Xcelerate commenced implementation of a new business plan that encompasses two separate but related businesses within the medical industry, including (i) owning and licensing the rights to various forms of medical equipment and portfolio of patents, patents pending and technology licenses and (ii) development of virtual health technology to assist patients in developing countries obtain medical care by extending the reach of physicians through the use of that technology. For more information visit www.xcelerate.global or contact us at 854-900-2020 or email info@xcelerate.global.
ABOUT ESN GROUP
ESN Group's 2 brands, Ceramedx and Earth Science Naturals are committed to using sustainable and eco-friendly natural plant based ingredients and component manufacturers. We don't test our finished products or ingredients on animals and neither do our suppliers or any third parties. Ceramedx® is the first natural ceramide therapy system developed in consultation with dermatologists for dry, sensitive skin. Earth Science is dedicated to providing clean and effective skin, body, and hair care solutions created with plant-based ingredients from more healthful sources for sustainability and wellness.
SAFE HARBOR
This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) the Company's financing plans; (ii) trends affecting the Company's financial condition or results of operations; (iii) the Company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend," and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control, and actual results may differ materially from those projected in forward-looking statements resulting from various factors.
SOURCE: Xcelerate
View the original press release on accesswire.com
FAQ
What type of funding did Xcelerate (XCRT) secure in October 2023?
How will Xcelerate (XCRT) use the new funding announced in October 2023?
Is the new funding announced by Xcelerate (XCRT) dilutive to shareholders?
